News & media
-
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
-
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes
-
Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)
-
Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts
-
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
-
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026
-
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology
-
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)
-
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity
-
Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)
-
Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome
-
Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)
Corporate management
-
Adam Steensberg - President and Chief Executive Officer
-
Adam Steensberg - President and Chief Executive Officer
-
Adam Steensberg - President and Chief Executive Officer
-
Henriette Wennicke - Executive Vice President and Chief Financial Officer
-
-
David Kendall - Executive Vice President, Research & Development and Chief Medical Officer
-
Ivan Møller - Executive Vice President and Chief Operating Officer
-
Utpal Singh - Executive Vice President and Chief Scientific Officer
-
Utpal Singh - Executive Vice President and Chief Scientific Officer
-
Steven Johnson - Executive Vice President, Chief Development Officer
-
Eric Cox - Executive Vice President, Chief Commercial Officer
Research and development
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
Sustainability
-
Morten Lagstrøm - ESG Officer
Logos and icons
-
)
Zealand Pharma Logo (RGB)
Stay up-to-date with the latest news from Zealand
Sign-up to receive press releases and company announcements directly to your inbox
Investor and Media contacts
